Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Published: |
Elsevier,
2016-12-15T19:25:49Z.
|
Subjects: | |
Online Access: | Get fulltext |